anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
An anal fissure is a small tear in the thin tissue (mucosa) that lines the anus. Anal fissures typically cause pain and bleeding with bowel movements. The cause is not fully understood, but low intake of dietary fiber may be a risk factor. Chronic anal fissure was defined as a split or ulceration in the posterior or anterior anoderm for at least 6 weeks: have distinct anatomic features such as muscle fibers visible in the wound. Anal fissures can be attributed to constipation or repeated straining: a hard fecal bolus cut the mucosa of anal canal that is relatively thigh at sphincter level management and optimal treatment of the disease is controversial. Many studies recommend conservative and medical treatment modalities as the initial treatment options since they are non-invasive and do not have risks such as anal sphincter injury. Lateral internal sphincterotomy (LIS) is considered the gold standard for treatment of chronic anal fissure. Nonetheless, anal incontinence is one of the worrisome complications of LIS. Fissurectomy is another option among those techniques which address the issues with LIS. LigaSure© (Valleylab) is a bipolar electrosurgical device designed to deliver high current and very low voltage to tissue. It monitors tissue impedance between the jaws of the instrument and continuously adjusts the delivery of energy. The use of LigaSure Small Jaw was never reported for anal fissures in literature. We have applied the use of this device to a group of patients complaining for chronic anal fissure in order to verify if there is any advantage to perform it compared to traditional technique (blade, scissors, electrocautery).
PURPOSE:To produce an antiurokinase antibody, by cultivating a hybridized cell of murine B cells and myelomatous cells in a culture medium containing peptone obtained by the enzymic decomposition of animal meat, transferrin and bovine blood serum in a low concentration of the blood serum. CONSTITUTION:B cells, e.g. murine B cells, are subjected to the plasmogamy with myelomatous cells, e.g. murine myelomatous cells, by the well-known method to give a hybridized cell capable of producing an antibody, which is then cultivated in a culture medium obtained by adding 0.5-10mg/ml peptone prepared by the enzymic decomposition of animal meat, 0.4-250mug/ml transferring and 0.1% (V/V) or more bovine blood serum to the well-known basic culture medium, e.g. NO.199 or Ham's F-10 culture medium, at 6-8 pH and 25-40 deg.C. The produced antibody is then recovered from the culture fluid separated from the cells by the conventional method.
PURPOSE: To obtain a therapeutic solution containing aristolactam and useful for the therapy of neuropathy such as Parkinsonian syndromes a Alzheimer's disease or for the therapy of copulative impotence. CONSTITUTION: This therapeutic solution contains aristolactam, preferably taliscanin extracted from the root of Aristolochia taliscana belonging to the genus Aristolochia, as an active ingredient. The solution preferably comprises 15-30vol.% of ethanol and water. The taliscanin is administered at a daily dose of 280-4000μg. Especially for the therapy of Parkinsonian syndromes, the taliscanin is administered at a daily dose of 280μg. When the effect of the therapy does not appear, the daily dose of the taliscanin is increased to 600μg. When the effect of the treatment does further not appear, the daily dose is increased with 280μg portions of the taliscanin, and the increase of the daily dose is continued, until the effect of the therapy appears or until the daily dose reaches 4000μg.  For four to six months after the start of the therapy, a hyaluronic acid-decomposing enzyme is preferably intramuscularly administered at a dose of 1ml per week.
The public's health is gravely at risk due to the current global outbreak of emerging viruses, specifically SARS-CoV-2 and MPXV. Recent studies have shown that SARS-CoV-2 mutants (such as Omicron) exhibit a higher capability to antagonize the host innate immunity, increasing their human adaptability and transmissibility. Furthermore, current studies on the strategies for MPXV to antagonize the host innate immunity are still in the initial stages. These multiple threats from emerging viruses make it urgent to study emerging virus-host interactions, especially the viral antagonism of host antiviral innate immunity. Given this, we selected several representative viruses that significantly threatened human public health and interpreted the multiple strategies for these viruses to antagonize the host antiviral innate immunity, hoping to provide ideas for molecular mechanism research that emerging viruses antagonize the host antiviral innate immunity and accelerate the research progress. The IAV, SARS-CoV-2, SARS-CoV, MERS-CoV, EBOV, DENV, ZIKV, and HIV are some of the typical viruses. Studies have shown that viruses could antagonize the host antiviral innate immunity by directly or indirectly blocking antiviral innate immune signaling pathways. Proviral host factors, host restriction factors, and ncRNAs (microRNAs, lncRNAs, circRNAs, and vtRNAs) are essential in indirectly blocking antiviral innate immune signaling pathways. Furthermore, via controlling apoptosis, ER stress, stress granule formation, and metabolic pathways, viruses may antagonize it. These regulatory mechanisms include transcriptional regulation, post-translational regulation, preventing complex formation, impeding nuclear translocation, cleavage, degradation, and epigenetic regulation.
PURPOSE: In patients with urologic chronic pelvic pain syndrome (UCPPS), the presence of widespread pain appears to identify a distinct phenotype, with a different symptom trajectory and potentially different response to treatment than patients with pelvic pain only.
MATERIALS AND METHODS: A 76-site body map was administered four times, at weekly intervals, to 568 male and female UCPPS participants in the MAPP Network protocol. The 76 sites were classified into 13 regions (1 pelvic region and 12 nonpelvic regions). The degree of widespread pain was scored from 0 to 12 based on the number of reported nonpelvic pain regions. This continuous body map score was regressed over other measures of widespread pain, with UCPPS symptom severity, and with psychosocial variables to measure level of association. These models were repeated using an updated body map score (0-12) that incorporated a threshold of pain ≥ 4 at each site.
RESULTS: Body map scores showed limited variability over the 4 weekly assessments, indicating that a single baseline assessment was sufficient. The widespread pain score correlated highly with other measures of widespread pain and correlated with worsened UCPPS symptom severity and psychosocial functioning. Incorporating a pain severity threshold ≥4 resulted in only marginal increases in these correlations.
CONCLUSIONS: These results support the use of this 13-region body map in the baseline clinical assessment of UCPPS patients. It provides reliable data about the presence of widespread pain and does not require measurement of pain severity, making it relatively simple to use for clinical purposes.
Marplan is indicated for the treatment of depression. Because of its potentially serious side effects, Marplan is not an antidepressant of first choice in the treatment of newly diagnosed depressed patients.

The efficacy of Marplan in the treatment of depression was established in 6-week controlled trials of depressed outpatients. These patients had symptoms that corresponded to the DSM-IV category of major depressive disorder; however, they often also had signs and symptoms of anxiety (anxious mood, panic, and/or phobic symptoms) (see CLINICAL PHARMACOLOGY).

A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation.

The antidepressant effectiveness of Marplan in hospitalized depressed patients, or in endogenomorphically retarded and delusionally depressed patients, has not been adequately studied.

The effectiveness of Marplan in long-term use, that is, for more than 6 weeks, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use Marplan for extended periods should periodically evaluate the long-term usefulness of the drug for the individual patient.
The present invention relates to a body balance measuring system capable of measuring body balance of a plurality of measurers within a constant measuring area. The body balance measuring system according to the present invention comprises: a plurality of exercise ability measuring devices; a guide unit; a heart rate measuring unit; a data transmitting unit; a plurality of signal sensing units; and a schedule managing server. The plurality of exercise ability measuring devices are provided in the measuring area. The guide unit guides movement information in the measuring area and information related to an exercise ability measuring mission to be performed by using the exercise ability measuring devices to the measurers. The heart rate measuring unit is attached to each measurer, and measures body information of each measurer. The data transmitting unit is attached to each measurer, and transmits identification information, signal strength information (RSSI), and the body information of the measurer measured from the heart rate measuring unit. The plurality of signal sensing units are provided around a movement path of the measurer within the measuring area and the exercise ability measuring devices, and receive and relay pilot signals and body information of the measurer transmitted from the data transmitting unit. The schedule managing server identifies a measurer who sent a signal by receiving the identification, signal strength information, and the body information from the signal sensing unit, and transmits distribution information to the guide unit to distribute the plurality of measurers to the plurality of exercise ability measuring devices by sensing a position of the measurer within the measuring area. The present invention can maximize an exercise effect.
The bioproducts are isolated by fractioning of intestine mucous cells of pigs, extraction with acetic acid, deposition with ethyl alcohol, ultrafiltration, lyophilization and gelfiltration. The antitumour agents IEG1 and IEG2 were tested under experimental conditions. IEG1 is peptide formed of 33 amino acid residues bonded by two guanyl ressidues with M.m. 4450 180 Da, and IEG 2 is guanazyl-hexapeptide with M.m. 950 120 Da. Both agents suppress the DNA synthesis. IEG1 manifests antitumour effect on three levels: in vitro in malignant cellular lines, in vivo, and in combination thereof.
FIELD: microbiology. SUBSTANCE: invention relates to the strain of intraspecies hybrid cells of Suis domestica. Strain shows all properties typical for hybrid cells and ensures to identify pig plague classic virus and provides its preparing at titers 5.5-6.5. Strain is deposited in VSKK (SHG) at N 48. EFFECT: new strain of cells indicated above. 1 tbl
Upper endoscopy (EGD) is employed to diagnose BE; however, the cost and invasiveness of this diagnostic tool limits its utilization in many patients (17). There is a need for an alternative, simple, and less invasive diagnostic tool for evaluating GERD patients and screening for BE. Esophageal capsule endoscopy (ECE) is a novel technique that offers non-invasive evaluation of esophageal pathology in gastroesophageal reflux disease (GERD) patients. The potential benefits of screening patients by Capsule Endoscopy (CE) are several. Detection of esophageal pathology during CE could select a subgroup of patients for upper endoscopy avoiding the risks and costs of an upper endoscopy in the majority. Other benefits include convenience, ability to perform the test on an outpatient basis in less than 30 minutes, patient acceptability, minimal loss of work time, safety, tolerability, the ability of non-physicians to screen patients, and potentially, improved compliance with screening recommendations. Recently, a new, high resolution capsule (ESO 2) with a larger field of view and better illumination than the previous CE has been introduced. A simplified ingestion protocol for CE that improves visualization of the Z-line has also been reported as well (17).
FIELD: medicine, sexology, pharmacy. SUBSTANCE: invention proposes medicinal form decomposing for 1-60 s after its placing into mouth cavity. This form presents mixture comprising from 0.05 to 5 mg of dopamine agonist and from 10 to 100 mg of testosterone. Invention relates also to method of treatment of disturbance of male erectile function. This form can comprise an opioid antagonist additionally. Invention removes by-side effects of dopamine agonist (sedative effect, breathing suppression, hypotension, bradycardia, perspiration and yawning) in the treatment process. Opioid antagonist counteracts to vomiting effects of dopamine agonist and in expands assortment of agents of indicated designation as a whole. EFFECT: enhanced effectiveness of drugs, valuable medicinal properties. 9 cl, 1 dwg, 15 tbl, 16 ex
PURPOSE: A pharmaceutical composition and health functional food containing crude drug extract is provided to prevent and treat neurodegenerative diseases. CONSTITUTION: A pharmaceutical composition for preventing and treating neurodegenerative diseases contains mixture crude drug extract containing Dioscorea Rhizoma and Dioscorea nipponica as an active ingredient, and pharmaceutically acceptable carriers. The neurodegenerative diseases include Alzheimer's disease, Creutzfeldt-Jakob disease, Huntington's disease, multiple sclerosis, guillain-Barre syndrome, or Parkinson's disease. A health functional food composition for preventing and treating neurodegenerative diseases contains the crude drug extract. The crude drug extract is prepared in the form of powder, granules, tablets, capsules, syrups, or drinks. [Reference numerals] (AA) Control group; (BB) Dioscorea Rhizoma/Dioscorea nipponica=3.5:1 mixed extract
The present disclosure provides a household sleeping monitoring system, comprises: an access point, a first electronic device and a second electronic device. The first electronic device includes an audio monitoring circuit, a signal processing and control circuit, a storage unit and a communication circuit. The audio monitoring circuit is used to detect a breathing sound signal generated by a breathing sound emitted from a subject during a first sleeping time. The signal processing and control circuit is electrically connected to the audio monitoring circuit. The storage unit is electrically connected to the signal processing and control circuit. The communication circuit is electrically connected to the signal processing and control circuit. The signal processing and control circuit is used to calculate a sleep breathing parameter based on the breathing sound, and the audio monitoring circuit records the breathing sound and stores it in the storage unit. The second electronic device includes a sound analysis module. The sound analysis module reads the sleep breathing parameter through the access point and then classifies the sleep breathing parameter and outputs a result of a sleep breathing event classification based on a comparison between the sleep breathing parameter and a threshold for a sleep breathing event.
A superficial peritoneal window will be made over the right part of the sacral promontory and extended caudally over the right outer border of the mesorectum down to the right side of the pouch of Douglas. In females, the vagina will be retracted anteriorly and a careful dissection of the rectovaginal septum will be performed down to the pelvic floor. A strip of polypropylene (3×20 cm) mesh will be introduced and sutured as distally as possible on the anterior rectal wall/ perineal body with three, interrupted nonabsorbable sutures.The posterior wall of the vagina will be fixed to the mesh using absorbable sutures. The mesh is then secured tension-free to the sacral promontory using three absorbable sutures. The mesh will be peritonealized by suturing the free edges of the previously divided peritoneum over the mesh to provide additional ventral elevation of the enterocele and avoid small bowel adhesions to the mesh.
Although phytochemicals are plant-derived toxins that are primarily produced as a form of defense against insects or microbes, several lines of study have demonstrated that the phytochemical, quercetin, has several beneficial biological actions for human health, including antioxidant and inflammatory effects without side effects. Quercetin is a flavonoid that is widely found in fruits and vegetables. Since recent studies have demonstrated that quercetin can modulate neuronal excitability in the nervous system, including nociceptive sensory transmission via mechanoreceptors and voltage-gated ion channels, and inhibit the cyclooxygenase-2-cascade, it is possible that quercetin could be a complementary alternative medicine candidate; specifically, a therapeutic agent against nociceptive and pathological pain. The focus of this review is to elucidate the neurophysiological mechanisms underlying the modulatory effects of quercetin on nociceptive neuronal activity under nociceptive and pathological conditions, without inducing side effects. Based on the results of our previous research on trigeminal pain, we have confirmed in vivo that the phytochemical, quercetin, demonstrates (i) a local anesthetic effect on nociceptive pain, (ii) a local anesthetic effect on pain related to acute inflammation, and (iii) an anti-inflammatory effect on chronic pain. In addition, we discuss the contribution of quercetin to the relief of nociceptive and inflammatory pain and its potential clinical application.
Atherosclerosis is an inflammatory disease of the arterial walls and represents a significant health problem in developed nations. Described is a targeted Magnetic Resonance Imaging (MRI) contrast agent for in vivo imaging of early stage atherosclerosis. Early plaque development is characterized by the influx of macrophages, which express a class of surface receptors known collectively as the scavenger receptors (SR). The macrophage scavenger receptor class A (SRA) is highly expressed during early atherosclerosis. The macrophage SRA therefore presents itself as an ideal target for labeling of lesion formation. By coupling a known ligand for the scavenger receptor, dextran sulfate, to a MRI contrast agent, early plaque formation can be detected in vivo. Targeted MR contrast agents offer a unique opportunity to visualize early plaque development in vivo with high sensitivity and resolution, allowing or early diagnosis and treatment of atherosclerosis.
Participants will be instructed to substitute a minimum of 5h/day of sitting with ≥2 h of light-intensity physical activity and ≥3 h of standing. Participants will be advised to rise from the seated position for 2-5 min every 30 min to engage in standing /light-intensity physical activities to interrupt their sitting.
Patients with lower ureteric stone will be randomized through permuted block randomization equally into two group. 120 patients will be on tamsulosin 0.4 mg once daily, therapy will be given for a maximum of 4 weeks.
BACKGROUND: Atherosclerosis is a chronic inflammatory disease causing a fatal plaque rupture, and its key aspect is a failure to resolve inflammation. We hypothesize that macrophage-targeted near-infrared fluorescence emitting photoactivation could simultaneously assess macrophage/lipid-rich plaques in vivo and facilitate inflammation resolution.
METHODS: We fabricated a Dectin-1-targeted photoactivatable theranostic agent through the chemical conjugation of the near-infrared fluorescence-emitting photosensitizer chlorin e6 and the Dectin-1 ligand laminarin (laminarin-chlorin e6 [LAM-Ce6]). Intravascular photoactivation by a customized fiber-based diffuser after administration of LAM-Ce6 effectively reduced inflammation in the targeted plaques of atherosclerotic rabbits in vivo as serially assessed by dual-modal optical coherence tomography-near-infrared fluorescence structural-molecular catheter imaging after 4 weeks.
RESULTS: The number of apoptotic macrophages peaked at 1 day after laser irradiation and then resolved until 4 weeks. Autophagy was strongly augmented 1 hour after the light therapy, with the formation of autophagolysosomes. LAM-Ce6 photoactivation increased the terminal deoxynucleotidyl transferase dUTP (deoxyuridine triphosphate) nick end labeling/RAM11 (rabbit monocyte/macrophage antibody)- and MerTK (c-Mer tyrosine kinase)-positive cells in the plaques, suggesting enhanced efferocytosis. In line with inflammation resolution, photoactivation reduced the plaque burden through fibrotic replacement via the TGF (transforming growth factor)-β/CTGF (connective tissue growth factor) pathway.
CONCLUSIONS: Optical coherence tomography-near-infrared fluorescence imaging-guided macrophage Dectin-1-targetable photoactivation could induce the transition of macrophage/lipid-rich plaques into collagen-rich lesions through autophagy-mediated inflammation resolution and TGF-β-dependent fibrotic replacement. This novel strategy offers a new opportunity for the catheter-based theranostic strategy.
The 17-pivaloyloxymethyl-3-methoxy morphinan deriv. of formula (I) is prepd. by reacting a dextromethorphan of formula (II) with a 2, 2, 2-trichloroethyl chloroformate in the presence of an organic solvent i.e. benzene to obtain a N-(2, 2, 2-trichloroethoxy carbonyl)-3-methoxy morphinan, reacting the obtd. cpd. with zinc in the presence of acetic acid to obtain 3-methoxy morphinan tetraacetate zincate, reacting the obtd. cpd. with sodium hydroxide in the presence of chloroform to obtain 3-methoxy morphinan, and reacting the obtd. cpd. with chloromethyl pivalate in acetone in the presence of a trimethyl amine. The deriv. (I) has a good analgesic and antitussive effect for mammals.
The incidence of menstrual disorders declines during adolescence. This has long been attributed to the gradual "maturation" of the hypothalamic-pituitary-ovarian axis, but the mechanism of this "maturation" is not known. Ovarian function critically depends on the pulsatile secretion of gonadotropin-releasing hormone (GnRH) by the hypothalamus and on the consequent and more readily assessed pulsatility of luteinizing hormone (LH) secretion by the pituitary. LH pulsatility has been shown to depend on energy availability, operationally defined as dietary energy intake minus exercise energy expenditure. The effects of energy availability on LH pulsatility are thought to be mediated by certain metabolic substrates and hormones.

Comparison: By manipulating diet and exercise regimens, contrasting energy availability treatments of 10 and 45 kilocalories per kilogram of fat-free mass per day are being administered to adolescents with 5-8 years of gynecological age and to adults with 14-18 years of gynecological age for five days in the early follicular phase of separate menstrual cycles. Effects of low energy availability on LH pulsatility and on selected metabolic substrates and hormones are being measured.